Darolutamide Receives EU Approval for Additional Indication in Prostate Cancer

The European Commission hasdgranted marketing authorization in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.